Results 231 to 240 of about 55,857 (266)

Percutaneous Deployment of the Sinus‐SuperFlex‐DS Stent for Hybrid Stage I Palliation in Neonates Weighing ≤ 2.5 kg: A Multicenter Study

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Hybrid stage I palliation (HS1P) has developed as an alternative to the Norwood stage I palliation for neonates with hypoplastic left heart and related left‐sided obstructive lesions. HS1P is currently used in various clinical settings, such as single ventricle palliation, bridge to decision, bridge to biventricular repair, or ...
Johanna Hummel   +8 more
wiley   +1 more source

Platelet FcɣRIIa Expression Refines Clinical Risk Assessment After Myocardial Infarction

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background In patients with myocardial infarction (MI), quantifying expression of platelet FcɣRIIa (pFCG) stratifies risk of subsequent MI, stroke, and death. Aims Assess the prognostic implications of clinical risk alone and in combination with the pFCG test.
David J. Schneider   +9 more
wiley   +1 more source

Pathophysiologic Consequences of Early Coarctation Stenting in a Longitudinal Porcine Model

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Novel stent technologies offer early intravascular treatment options for coarctation (COA). Mid‐to‐long‐term cardiovascular responses to early COA stent interventions are undefined. Aims We studied a porcine model of COA, with and without early stent implantation with serial dilation to adult aortic diameters, aiming to define ...
Leah M. Gober   +7 more
wiley   +1 more source

A White Paper on Advancing Long‐Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
As use cases for long‐acting therapeutics expand across clinical indications, there is a critical need to ensure the inclusion of women who are pregnant or breastfeeding, infants and children—populations with a historical gap in the availability of interventions already approved for use in adults.
Moherndran Archary   +59 more
wiley   +1 more source

Impact of CYP2C19 and CYP3A4 Inhibitor Use on Clopidogrel Clinical Effectiveness in CYP2C19 Genotyped Patients Undergoing Percutaneous Coronary Intervention

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
CYP2C19 and CYP3A4 contribute to clopidogrel bioactivation. CYP2C19 no‐function alleles diminish clopidogrel's antiplatelet effects and clinical effectiveness. Coadministration of either a CYP2C19 or a CYP3A4 inhibitor may also reduce clopidogrel's antiplatelet effects and lead to phenoconversion in patients without a CYP2C19 no‐function allele (normal/
Danwei Shao   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy